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Abstract 
 
Myelin is essential for rapid and accurate conduction of electrical impulses by 
axons in the central and peripheral nervous system. Myelin is formed in the early 
postnatal period, and developmental myelination in the peripheral nervous 
system (PNS) depends on axonal signals provided by Nrg1/ErbB receptors. In 
addition, Nrg1 is required for effective nerve repair and remyelination in 
adulthood. We discuss here similarities and differences in Nrg1/ErbB functions in 
developmental myelination and remyelination after nerve injury.  
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Introduction 
 
Communication between cells is fundamental for formation and regeneration of 
organs. We know today that only a handful of important signaling systems are 
used for cell communication during development, and receptor tyrosine kinases 
are prominent among them. Many receptor tyrosine kinases were identified 
because of their oncogenic potential when mutated, and the non-mutant variants 
(the proto-oncogenes) function in development (Schlessinger, 2000). Recent 
evidence demonstrates that these receptors are frequently reused in the adult 
where they orchestrate regeneration.   
 
Neuregulins (Nrgs, in humans called heregulins HRGs) are a family of growth 
factors that display sequence similarities with epidermal growth factor (EGF) 
(Falls, 2003). The factors signal via tyrosine kinase receptors of the ErbB (in 
humans called HER) family (Yarden and Sliwkowski, 2001). Nrgs/ErbBs were 
identified and intensely studied because of their functions in cancer. Antibodies 
against the receptors or small molecular weight inhibitors that interfere with their 
activity are used in cancer therapy and provide excellent tools for functional 
studies (Hynes and Lane, 2005). Among the different members of the family, 
Neuregulin-1 (Nrg1) is the most important and the best-studied. Nrg1 is one of 
the largest genes in the human genome and spans almost two megabases. From 
this gene, many different isoforms are produced by alternative splicing and the 
usage of different promoters (Falls, 2003). All Nrg1 isoforms contain an EGF-like 
domain embedded in otherwise divergent sequences, and the EGF-like domain 
is sufficient to bind and activate ErbB receptors. Major classes of Nrg1 isoforms 
use different promoters and are expressed in a characteristic and distinct pattern, 
for instance type III mainly by neuronal cells, and type I Nrg1 by a few restricted 
neuronal cell types and by mesenchymal cells of many organs (Meyer and 
Birchmeier, 1995). Interestingly, different isoforms take over distinct functions in 
vivo. For instance type III and type I Nrg1 are produced by all or just a subset of 
sensory neurons, respectively, and have distinct functions in myelination and 
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muscle spindle induction (Meyer and Birchmeier, 1995; Hippenmeyer et al., 
2002; Perlin et al., 2011; Cheret et al., 2013). Nrg1 isoforms are produced as 
soluble membrane-bound proteins. Membrane-bound variants can be released 
by proteases, or they remain bound to the cell surface after proteolysis (Falls, 
2003). Because Nrg1 can be shed or remain membrane-bound, the receptors 
detect signals provided by distant or directly neighboring cells (paracrine 
signaling). In addition, occasionally the same cell produces and receives the 
signal (autocrine signaling). Thus, the diversity of the Nrg1 isoforms contributes 
to the versatility of the signaling system. 
 
Important Nrg1 functions were identified by genetics, mainly in mice but also in 
zebrafish. Responses to Nrg1 are astonishingly diverse, and encompass 
migration, cell fate decisions, morphogenesis, proliferation and the control of cell 
size. Moreover, glial cells, neurons, muscle and epithelial cells respond to Nrg1. 
Prominent among the Nrg1 functions is its role in PNS development and 
regeneration. In particular, the myelinating glia of the PNS, Schwann cells, 
depend on Nrg1, and we concentrate on discussing this function here. In 
Schwann cells, the Nrg1 signal is mediated by two receptors, ErbB2 and ErbB3 
(Woldeyesus et al., 1999), and these receptors are unusual in the respect that 
ErbB3 lacks tyrosine kinase activity, whereas ErbB2 is a ligand-less receptor 
(Citri et al., 2003). They function as heterodimers where ErbB2 and ErbB3 
provide the tyrosine kinase and the ligand binding activity, respectively. Nrg1 
binding to ErbB2/3 results in receptor tyrosine phosphorylation, which triggers 
recruitment of adaptors and enzymes and culminates in the activation of 
signaling cascades (Schlessinger, 2000; Yarden and Sliwkowski, 2001). 
 
 
Schwann cell precursors 
 
Schwann cells depend on Nrg1 signaling for their development. Schwann cells 
derive from neural crest and Schwann cell precursors are defined by their 
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anatomical position, i.e. they associate with axons of peripheral nerves. Schwann 
cells depend on Nrg1/ErbB signaling for migration along the axon tracts and for 
proliferation, and are basically absent in mice or zebrafish that lack Nrg1, ErbB2 
or ErbB3 (Meyer and Birchmeier, 1995; Riethmacher et al., 1997; Woldeyesus et 
al., 1999; Lyons et al., 2005; Perlin et al., 2011). The Nrg1 signal that drives 
Schwann cell development is provided by neurons, and presented in the 
axolemma. Thus, axonal membranes are mitogenic for Schwann cell precursors, 
and the mitogenic agent is Nrg1 (Dong et al., 1995; Morrissey et al., 1995; 
Schroering and Carey, 1998). Genetic evidence demonstrates that type III Nrg1 
drives Schwann cell development (Meyer et al., 1997); this isoform can remain 
membrane-bound after proteolytic cleavage (Cabedo et al., 2002). 
 
Schwann cell precursors retain characteristics of neural crest cells and remain 
pluripotent (Morrison et al., 1999). They generate immature Schwann cells, 
endoneurial fibroblasts of fetal nerves as well as melanocytes, parasympathetic 
neurons and odontoblasts (Joseph et al., 2004; Adameyko et al., 2009; Dyachuk 
et al., 2014; Espinosa-Medina et al., 2014; Kaukua et al., 2014). Schwann cell 
progenitors give rise to immature Schwann cells around E16 (Jessen et al., 
2015). This transition is associated with axon wrapping, appearance of a basal 
lamina around Schwann cells, and formation of the perineural sheath. 
Subsequently, Schwann cells sort and wrap axons, and they generate the 
multilayered myelin sheaths. 
 
Entry into the myelination program 
 
Myelination is essential for neuronal function, and deficits in myelination cause 
devastating disease (Suter and Scherer, 2003; Quarles et al., 2006; Nave and 
Trapp, 2008). Myelin electrically insulates axons and allows fast propagation of 
nerve impulses by saltatory conduction. The overall conduction velocity of the 
myelinated axon is determined by myelin and axonal thickness, internodal length 
and myelin integrity (Waxman, 1980; Court et al., 2004). The overall organization 
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of the myelin sheath is similar in the PNS and CNS, but substantial differences 
exist in development, assembly and molecular composition of the myelin, or in 
the extrinsic signals and transcription factors that drive myelination (Quarles et 
al., 2006; Brinkmann et al., 2008; Emery, 2013; Hornig et al., 2013). We discuss 
here the molecular processes active during peripheral myelination.  
 
Myelination is tightly controlled by axons. Only medium and large diameter axons 
are myelinated, and thin axons (smaller than 1 µm) are ensheathed by non-
myelinating Schwann cells and are organized in bundles (called Remak bundles; 
Hillarp and Olivecrona, 1946). Thin and thick myelinated axons have thin and 
thick myelin sheaths, respectively. This leads to the constant G-ratio (defined as 
ratio of axonal diameter to diameter of the myelinated fiber) of 0.67 (Donaldson 
and Hoke, 1905). Thus, the axon provides cues that determine its myelination 
fate and the thickness of its myelin sheath. Conversely, Schwann cell-derived 
signals allow neuronal survival by providing trophic signals and/or metabolic 
support (Riethmacher et al., 1997; Viader et al., 2013). Interactions between 
Schwann cells and axons also guide cell adhesion molecules and ion channels 
into distinct axonal domains, the nodes of Ranvier and internodes, a pre-requisite 
for efficient saltatory conduction (Eshed-Eisenbach and Peles, 2013). Finally, 
intact myelin provides signals for radial axonal growth and enhances axonal 
transport, which is impaired in demyelinating diseases (de Waegh et al., 1992; 
Watson et al., 1994; Kiryu-Seo et al., 2010; Saxton and Hollenbeck, 2012).  
 
The surface membrane of Schwann cells was estimated to increase during 
myelination up to several thousand-fold. Therefore, myelination is accompanied 
by the production of huge amounts of myelin proteins and lipids. The entry into 
the myelination program in Schwann cells is controlled on the transcriptional level 
by factors like Egr2 (Krox-20), Pou3f1 (Oct-6/Scip/Tst-1) and Pou3f2 (Brn2) that 
interact with Sox10 to drive expression of myelin genes (Topilko et al., 1994; 
Bermingham et al., 1996; Jaegle et al., 2003; Finzsch et al., 2010; see also 
Svaren and Meijer, 2008, and the references herein). In addition, lipid 
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biosynthesis genes are coordinately regulated, and the Srebp/Scap transcription 
factors and the control of their expression play important roles in lipid production 
(Verheijen et al., 2009; Norrmen et al., 2014). Extrinsic signals that trigger entry 
into myelination are provided by Nrg1/ErbB2/3, GPR126, integrins, extracellular 
matrix components and ADAM22/Lgi4 (Bermingham et al., 2006; Nave and 
Salzer, 2006; Ozkaynak et al., 2010; Taveggia et al., 2010; Raphael and Talbot, 
2011). Thus, the Nrg1/ErbB2/3 system that regulates expansion of the progenitor 
pool and migration in early Schwann cell development is unexpectedly reused for 
myelination. It was therefore discussed whether Nrg1 provides instructive or 
permissive signals during myelination (Lemke, 2006; Nave and Salzer, 2006). 
 
Nrg1 and other extrinsic signals that control myelination 
 
Nrg1 activates Ras/MAPK/Erk1/2, PI3K/Akt, PLCγ, focal adhesion kinase (FAK), 
Rho-GTPases and JNK, and these pathways have been implicated in 
myelination using mouse genetics or cell culture experiments (Newbern and 
Birchmeier, 2010). Cell culture models are frequently used to study entry into 
myelination and are combined with pharmacological inhibitors, overexpression 
through viral transduction and interfering RNAs. Results obtained with such 
methods can vary according to the exact culture conditions. Such studies mainly 
implicated PI3K/Akt as key signals in myelination, and suggested that MAPK/Erk 
played a limited role or even drive Schwann cells into dedifferentiation (Maurel 
and Salzer, 2000; Harrisingh et al., 2004; Ogata et al., 2006). Unexpectedly, 
recent genetic experiments have now shown that MAPK/Erk signaling is a major 
positive regulator of myelination in vivo, indicating that this notion has to be 
revisited (Grossmann et al., 2009; Newbern et al., 2011; Ishii et al., 2013; 
Sheean et al., 2014). 
 
Erbin is an intracellular molecule that binds ErbB2 and modulates and promotes 
Nrg1 signaling and is essential for myelination (Tao et al., 2009). Shp2 mediates 
Nrg1 signals downstream of ErbB2/3 and is required for sustained activation of 
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MAPK/Erk1/2 as well as for Nrg1-evoked cellular responses like proliferation, 
migration or myelination, which are impaired when Shp2 is ablated in vivo 
(Grossmann et al., 2009). Furthermore, ablation of Erk1/2 in Schwann cells 
causes deficits that are remarkably similar to those observed in Shp2 or 
Nrg1/ErbB2/ErbB3 mutants (Newbern et al., 2011). Interestingly, mild activation 
of MAPK signaling releases Schwann cells from their dependence of Nrg1 
signaling during all stages of Schwann cell development and myelination 
(Sheean et al., 2014). In particular, MAPK/Erk positively regulate entry into 
myelination but a strong and sustained activation of Raf (and thus the 
Ras/MAPK/Erk cascade) results in demyelination, indicating that signaling 
strength determines the cellular response (Napoli et al., 2012).  
 
Pharmacological inhibition of PI3K/Akt in cultured Schwann cells enhances 
myelin gene expression and myelination in neuron/Schwann cell co-cultures 
(Maurel and Salzer, 2000; Ogata et al., 2006). PTEN is a negative regulator of 
the PI3K/Akt pathway and, accordingly, loss of PTEN results in Akt activation. 
This leads to mild hypermyelination of small peripheral axons, and to locally 
restricted hypermyelination close to the nodes of Ranvier (Goebbels et al., 2010; 
Goebbels et al., 2012).  
  
The activator of adenylate cyclase, forskolin, has long been known to stimulate 
myelination in culture (Lemke and Chao, 1988; Morgan et al., 1991). In vivo, 
cAMP-mediated signals provided by the G protein-coupled receptor GPR126 are 
essential for myelination, and mutations of GPR126 preclude peripheral 
myelination in zebrafish and mice (Monk et al., 2009; Monk et al., 2011). 
Myelination in GPR126 mutant fish is rescued by forskolin in the swimming water 
(Monk et al., 2009). GPR126 is activated by binding to laminin and collagen, 
providing evidence that the extracellular matrix formed by immature Schwann 
cells provides signals that control entry into myelination (Paavola et al., 2014; 
Petersen et al., 2015). Integrin signaling also provides cues for myelination. 
Integrins are important adhesion and signaling receptors that recognize 
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extracellular matrix components like laminin, and upon binding to matrix they 
recruit intracellular molecules like FAK. Laminin, integrin and FAK provide 
essential cues for axonal sorting and myelination in vivo (Feltri et al., 2002; Chen 
and Strickland, 2003; Grove et al., 2007; Berti et al., 2011; Pellegatta et al., 
2013). Thus, GPR126 and integrins provide links to the extracellular matrix and 
signal in a matrix-dependent manner to control axonal sorting and myelination.  
 
Proteolytic processing is rate limiting for Nrg1 activity and function 
 
Many Nrg1 isoforms are synthesized as membrane-bound proteins and require 
proteolytic processing for function. Type I and type III Nrg1 are processed by 
Bace1, an aspartic-acid protease, and by members of the disintegrin and 
metalloproteinase (Adam) family (Horiuchi et al., 2005; Hu et al., 2006; Willem et 
al., 2006; Yokozeki et al., 2007; La Marca et al., 2011; Fleck et al., 2013). A 
single Bace1-cleavage of type I Nrg1 releases a soluble EGF-domain containing 
fragment, whereas cleavage of type III Nrg1 at a similar site generates an EGF-
domain containing fragment that remains associated with the membrane (Hu et 
al., 2006; Willem et al., 2006; Fleck et al., 2013). Systematic in vitro mapping 
demonstrates that protease cleavage sites exist that surround the EGF-like 
domain in type III Nrg1 (Hu et al., 2006; Willem et al., 2006; Fleck et al., 2013). 
Thus, small soluble EGF-domain containing peptides can be produced that are 
biologically active in vitro and in the zebrafish in vivo (Fleck et al., 2013). In 
addition, ADAM17 might cleave type III Nrg1 in the EGF-domain and thus 
destroy its activity but this cleavage site was not found in all reported mapping 
experiments (La Marca et al., 2011; Fleck et al., 2013).  
 
Genetic models demonstrated that Bace1-dependent cleavage of Nrg1 is 
physiologically important for its function. Thus, Bace1 mutant mice and zebrafish 
display deficits in developmental myelination. In addition, remyelination of 
peripheral nerves and formation and maintenance of muscle spindles are 
impaired in mice, and these phenotypes resemble the well-characterized ones 
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observed when Nrg1/ErbB signaling is ablated (Hu et al., 2006; Willem et al., 
2006; Cheret et al., 2013; Fleck et al., 2013). It should be noted that phenotypes 
in Bace1 mutants are not as strong as the ones observed in Nrg1 signaling 
mutants, indicating that other proteases participate in shedding. However, 
overexpression of type I Nrg1 in transgenic mice induces supernumerary muscle 
spindles in a strictly Bace1-dependent manner, indicating that this isoform 
requires Bace1 processing for its function (Cheret et al., 2013). The finding that 
Bace1 cleaves Nrg1 might be of interest for new therapies that are being 
developed for Alzheimer’s disease. Bace1 is essential for APP processing and 
amyloid peptide formation, and Bace1 inhibition is a strategy for treatment of 
Alzheimer’s disease. Adverse effects due to inhibition of other Bace1 substrates 
including Nrg1 must be considered (Fleck et al., 2012).  
 
Rates of protein synthesis control the end of myelination and myelin 
thickness  
  
During normal development, myelin is formed rapidly during the postnatal period. 
In particular, radial myelin growth is fast during the first two postnatal weeks in 
mice, slows in the maturing animal and ceases in adulthood. Recent data 
indicate that translational control mechanisms are important determinants that 
end myelination and thereby control myelin thickness (Pereira et al., 2010; 
Sheean et al., 2014). 
 
The control of protein synthesis in vivo is difficult to analyze due to technical 
limitations, and synthesis of myelin components have been little investigated. 
However, new methods are now available that are based on a pulse-labeling of 
proteins with stable (nonradioactive) isotope-labeled amino acids and on 
quantification of labeled and unlabeled proteins by mass spectroscopy (Selbach 
et al., 2008; Doherty et al., 2009; Schwanhausser et al., 2011; Sheean et al., 
2014). With these techniques it was possible to assess translational control 
mechanisms during myelination in the PNS and their dependence on MAPK/Erk 
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(Sheean et al., 2014). Similar mechanisms appear to be operative in myelination 
of the CNS (Michel et al., 2015). 
 
Protein synthesis rates are highly regulated. A rate-limiting step is the initiation of 
translation that is strongly enhanced by growth factor signaling mediated by mTor 
and MAPK. Sustained activation of MAPK overcomes the signals that end 
myelination and results in continuous myelin growth achieved by enhanced 
protein synthesis rates. MAPK exerts this effect in part by mTor-dependent 
signaling, possibly by regulating the negative regulator of mTor, TSC2, but also 
by mTor-independent mechanisms (Sheean et al., 2014). Further supporting 
evidence derives from the analysis of mTor mutant mice that arrest myelin 
growth prematurely and that form thin myelin (Sherman et al., 2012). Dlg1-PTEN 
interactions were also reported to control the end of myelination and thus myelin 
thickness, and might impinge on the control of protein synthesis (Cotter et al., 
2010).  
 
Nrg1 and remyelination after injury 
 
The potent role of Nrg1 as an axonal signal that drives virtually all stages of 
Schwann cell development and myelination provides a rationale for studying its 
function in peripheral nerve injury. Despite its importance in developmental 
myelination, Nrg1/ErbB signaling is not required for the maintenance of the 
myelin sheath in adulthood (Atanasoski et al., 2006; Fricker et al., 2011; Fricker 
et al., 2013). Injury radically alters the communication between axons, glia and 
immune cells, and effective signaling between these cells is crucial for successful 
nerve repair (Fawcett and Keynes, 1990; Scheib and Hoke, 2013). There is 
growing evidence that Nrg1 is important for repair and remyelination after injury, 
but signaling requirements in repair do not merely recapitulate requirements in 
development. Instead, differences exist in usage of Nrg1 isoforms and co-
operating signaling systems.  
 
 12 
Peripheral nerve injury has many causes ranging from traumatic damage to 
metabolic disturbances in diabetes mellitus. The primary pathology can affect 
axons (nerve transection) or Schwann cells, and their inter-dependence means 
that injury to one will ultimately affect the other. Fortunately, the PNS has a 
significant capacity for repair, and axons are able to regenerate over long 
distances and to remyelinate. This repair process leads to appreciable recovery 
of function after damage, but significant challenges remain: The clinical outcome 
after nerve injury often remains poor and there is no licensed therapeutic (Scheib 
and Hoke, 2013). The outcome depends on the injury type: Complete nerve 
transection has a worse outcome than nerve crush due to mis-directed axon 
growth, and proximal injuries also have a poorer outcome than distal ones due to 
the slow (1 mm/day) rate of axon regrowth (Fu and Gordon, 1995). In addition, 
aged Schwann cells are less supportive of axon outgrowth than young Schwann 
cells and might produce less efficiently beneficial growth and metabolic factors 
(Painter et al., 2014).  
 
Traumatic nerve injury is followed by stereotypic events called Wallerian 
degeneration, i.e. axonal degeneration, Schwann cell dedifferentiation and 
proliferation. Subsequently, axons begin to regenerate, Schwann cells 
redifferentiate and remyelinate and targets are reinnervated. Although similarities 
between development and repair of myelin are apparent, key differences exist, 
and for instance remyelinated axons have shorter internodes and thinner myelin 
sheaths (Fancy et al., 2011). Nevertheless, the reformed myelin enables rapid 
saltatory conduction.  
 
Traumatic nerve injury provides a model for the analyses of biological pathways 
important for nerve degeneration and repair, and the stereotypic events allow the 
quantitation of degeneration/regeneration (Conforti et al., 2014). Genetic mutants 
in invertebrates and vertebrates demonstrated that injury induces an active axon 
destruction program (Mack et al., 2001; McDonald et al., 2006; Osterloh et al., 
2012; Gilley et al., 2015). Schwann cells in the distal nerve stump lose their 
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axonal attachment, proliferate and resorb myelin. Autophagy of myelin by 
Schwann cells provides the rate-limiting mechanism for myelin clearance and 
depends on JNK/c-Jun (Gomez-Sanchez et al., 2015). The initial signal for the 
Schwann cell response appears to be provided by axons, as Wallerian 
degeneration slow (Wlds) mouse mutants whose axon destruction is delayed 
also show gross delays in myelin removal and nerve regeneration. The remaining 
myelin was proposed to inhibit axon outgrowth (Brown et al., 1994).  
 
An interesting concept that emerged over the last decade is that Schwann cells 
in the distal nerve stump display unique characteristics (they were also called 
‘repair cells’) and do not simply revert to an earlier developmental stage (Arthur-
Farraj et al., 2012; Jessen et al., 2015). These ‘repair cells’ are essential for 
nerve repair that requires axoglial signaling: Axon-derived signals promote 
differentiation of repair cells and growth factors released by them stimulate axon 
growth (Fawcett and Keynes, 1990; Jessen et al., 2015).  
 
Traumatic nerve injury results in the dysregulated expression of many 
components of the Nrg1 signaling pathway like increased expression of 
ErbB2/ErbB3 receptors and enhanced receptor activation in the distal nerve 
(Cohen et al., 1992; Carroll et al., 1997; Kwon et al., 1997). Neuronal type III 
Nrg1 expression declines after axon transection, but is restored as axons 
reinnervate their targets and may therefore depend on target-derived growth 
factors (Bermingham-McDonogh et al., 1997). After axon destruction, type I Nrg1 
expression in Schwann cells is transiently upregulated (Stassart et al., 2013).  
 
Remyelination depends on juxtacrine Nrg1 derived from the axolemma. Mice in 
which Nrg1 is genetically ablated in a subpopulation of axons (and not from 
Schwann cells) show absent or grossly impaired remyelination, and the deficit is 
restricted to those axons that lack Nrg1 (Fricker et al., 2011). Thus, axon derived 
type III Nrg1 plays a key role in remyelination. Schwann cell derived type I Nrg1 
modulates remyelination, and selective ablation of Nrg1 in Schwann cells does 
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not impair developmental myelination but impinges on remyelination and 
functional recovery after injury (Stassart et al., 2013). Thus, developmental 
myelination exclusively depends on axonal type III Nrg1, whereas Schwann cell-
derived type I Nrg1 contributes to remyelination. The protease Bace1 is required 
for full Nrg1 activity and remyelination is impaired in mice lacking Bace1 (Hu et 
al., 2008). Erbin expression increases in distal nerve after injury, and Erbin 
mutant mice display impaired remyelination and functional recovery (Liang et al., 
2012). The early phases of the injury response are not Nrg1 dependent: Myelin 
clearance is not delayed when Nrg1 is lacking, and Schwann cell proliferation 
during regeneration was not impaired in the absence of Nrg1 signaling 
(Atanasoski et al., 2006; Fricker et al., 2013). Finally, the inflammatory response 
is not Nrg1-dependent (Fricker et al., 2013).   
 
A further important difference between Nrg1 functions in development and repair 
exists: remyelination and functional recovery are greatly delayed when Nrg1 is 
absent, but ultimately large or medium diameter axons are remyelinated, 
whereas small diameter axons are wrapped but not myelinated (Fricker et al., 
2013). Therefore, Nrg1 determines the rate of remyelination after injury, but it 
neither decides the myelination fate (i.e. selects the axons that are remyelinated) 
nor the final outcome of remyelination. This is distinct from its developmental 
function where even a reduction in Nrg1 signaling results in reduced myelin 
thickness that is not compensated with time (Garratt et al., 2000; Michailov et al., 
2004). This result implies that signals cooperate with Nrg1 during repair, which 
are not operative during development (Fricker et al., 2011). Nrg1 might not only 
modulate  Schwann cell function during nerve repair, since the rate of axon 
regeneration was also reduced when Nrg1 was lacking. ‘Back signaling’ (i.e. the 
release of the intracellular domain of type III Nrg1 by gamma secretase; Hancock 
et al., 2011) or alternatively, indirect effects due to changed release of glial 
factors might contribute to this. 
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Can exogenous Nrg1 promote nerve repair and functional recovery after injury 
and thus be of therapeutic use? A successful outcome of a Nrg1 therapy may 
require just the right level of signaling, since excessive stimulation of Schwann 
cells is known to cause proliferation, demyelination, and formation of myelin that 
is too thick and possibly unstable (Zanazzi et al., 2001; Sheean et al., 2014). 
Moreover, Nrg1-dependent activation of ErbB receptors on Schwann cells (and 
other cell types exposed to Nrg1) could cause oncogenic transformation 
(Huijbregts et al., 2003). The final outcome of such a therapy is therefore likely to 
depend on the exact mode of Nrg1 delivery including timing of the treatment and 
dose. Despite these caveats, encouraging findings have emerged. For the 
treatment of cardiovascular disease, Nrg1 is already being tested in clinical trials 
and the treatment has a good safety profile (Jabbour et al., 2011). Transgenic 
over-expression of type I or type III Nrg1 in neurons promotes remyelination after 
traumatic nerve injury (Stassart et al., 2013). Furthermore, exogenous 
administration of type I and II Nrg1 protein or delivery of type I Nrg1 by viral 
vectors promotes axon outgrowth and nerve repair in experimental settings 
(Mahanthappa et al., 1996; Cai et al., 2004). Thus, the effects were not restricted 
to improved remyelination but also enhanced axonal outgrowth, which represents 
probably the critical factor in functional repair. 
 
Charcot-Marie-Tooth is an inherited neuropathy that affects approximately 1 in 
2500 people (Rossor et al., 2013). CMT1A, the most common variant of CMT, is 
caused by the duplication of a large region of chromosome 17 that includes the 
PMP22 gene, i.e. an excess of the myelin protein PMP-22. Thus, CMT1A affects 
primarily the myelin sheath and is associated with aberrant Schwann cell 
differentiation, myelination and demyelination. Administration of exogenous Nrg1 
during early postnatal development did overcome impaired peripheral 
myelination, prevented axon loss and ameliorated the impairment of nerve 
function (Fledrich et al., 2014).  
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Nrg1 also promotes the survival of terminal Schwann cells that envelop the 
neuromuscular junction, and these cells contribute to remodeling of the 
neuromuscular synapse after injury and to reinnervation of denervated synapses 
(Kang et al., 2014). The survival of terminal Schwann cells after neonatal 
denervation can be improved through Nrg1 administration, and they remain 
responsive to Nrg1 in adulthood (Trachtenberg and Thompson, 1996).  
 
 
In summary, Nrg1 is required for effective nerve repair in adulthood and acts 
during remyelination. Both type I and type III Nrg1 isoforms contribute to myelin 
repair, in contrast to the developmental myelination, which appears to be strictly 
type III dependent (Fig. 1). In contrast to developmental myelination, during 
repair the loss of the Nrg1 signal is partly compensated by other mechanisms. 
Exogenous Nrg1 helps to promote nerve repair in a number of different animal 
models ranging from traumatic nerve injury to hereditary neuropathy, and 
promotes axon outgrowth as well as myelin repair. It is thus an encouraging 
therapeutic candidate. Complex decisions will need to be made prior to its use in 
clinical trials in regards to optimal isoform/formulation, dose and timing of 
administration. 
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Fig. 1: Nrg1 signaling during developmental myelination and remyelination. 
 
Developmental myelination (A) depends on type III Nrg1 that is produced by 
peripheral sensory and motoneurons and presented in the axonal membrane. 
Nrg1 needs to be processed by Bace1 for full signaling activity. ErbB2/ErbB3 
receptors on Schwann cells recognize this signal and transmit it. Erbin, an 
intracellular ErbB2 interacting protein, is important for full activation of ErbB 
receptors. Many signaling components act downstream of Nrg1/ErbB, and we 
display here Shp2 and Erk1/2, because mutations of Nrg1/ErbB, Shp2 and 
Erk1/2 all produce very similar or even identical changes in Schwann cell 
development and myelination. Activation of MAPK, i.e. expression of an activated 
variant, can substitute for Nrg1/ErbB3/Shp2 during Schwann cell development 
and myelination. MAPK represents thus an important readout of Nrg1/ErbB 
signaling. Transcriptional and translational responses to the Nrg1 signal are 
observed in developmental myelination.  Remyelination after injury (B) reuses 
the Nrg1 signaling network, and remyelination and nerve repair are severely 
 18 
delayed in the absence of Nrg1. Two Nrg1 isoforms participate in remyelination, 
axonal type III and Schwann cell-derived type I. Full ErbB activation and efficient 
regeneration depend again on Bace1 and Erbin. 
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